Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after Administration of Anti-CA 125 Murine Monoclonal Antibody B43.13-Reference-Cited by-同舟云学术

Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after Administration of Anti-CA 125 Murine Monoclonal Antibody B43.13

Published:1995-04 Issue:2 Volume:14 Page:199-203
ISSN:0272-457X
Container-title:Hybridoma
language:en
Short-container-title:Hybridoma

Author:

MADIYALAKAN R.,SYKES T.R.,DHARAMPAUL S.,SYKES C.J.,BAUM R.P.,HÖR G.,NOUJAIM A.A.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/hyb.1995.14.199

Reference16 articles.

1. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma

2. Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC125 and B43.13

3. Idiotypic antibody immunotherapy of cancer

4. Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.

5. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen;Taiwanese Journal of Obstetrics and Gynecology;2024-01

2. Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125;Taiwanese Journal of Obstetrics and Gynecology;2023-11

3. Clinical application of radioiodinated antibodies: where are we?;Clinical and Translational Imaging;2022-01-11

4. MUC16 as a novel target for cancer therapy;Expert Opinion on Therapeutic Targets;2018-07-26

5. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis;Journal of Nuclear Medicine;2016-02-02